Security key
046513206
Atara Biotherapeutics, Inc. - Common Stock (ATRA)
CUSIP: 046513206
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 24
- Total 13F value
- $276
- Share change
- 0
- SEC-reported price per share
- $11.50
- Number of holders
- 1
- Shares outstanding
- 8,191,888
Holder snapshot
3 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
ATRA full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Atara Biotherapeutics, Inc. SEC filings
Atara Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 046513206
Recent filing periods:
Ownership snapshot
Top reported holders of ATRA - Atara Biotherapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Adiumentum Capital Fund I LP
Disclosed value leader
EcoR1 Capital, LLC
Comparable rows
15/15
Latest evidence
11 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
13D/G row: Adiumentum Capital Fund I LP
Showing 1-6 of 15 holder rows.
Quick read
Adiumentum Capital Fund I LP leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Adiumentum Capital Fund I LP's linked filing trail.
Comparable ownership
Top 5
Adiumentum Capital Fund I LP
20%
EcoR1 Capital, LLC
17%
Panacea Innovation Ltd
16%
Redmile Group, LLC
9.9%
Adage Capital Management, L.P.
8.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Adiumentum Capital Fund I LP |
3/4/5
13D/G
Director, Other*, 10%+ Owner
|
20%
from 13D/G
|
$10,487,308
1,586,588 shares
mixed-class rows
|
— | 16 May 2025 |
| EcoR1 Capital, LLC |
3/4/5
13D/G
13F
10%+ Owner · Company
|
17%
from 13D/G
|
$14,511,200
1,552,000 shares
|
+$4,744,255 | 07 May 2026 |
| Panacea Innovation Ltd |
3/4/5
13D/G
10%+ Owner · Panacea Innovation Limited
|
16%
from 13D/G
|
$11,921,613
1,011,000 shares
mixed-class rows
|
-$2,308,226 | 07 May 2026 |
| Redmile Group, LLC |
3/4/5
13D/G
13F
Director · Company
|
9.9%
from 13D/G
|
$3,356,927
441,701 shares
|
— | 16 May 2025 |
| Adage Capital Management, L.P. |
13D/G
|
8.6%
|
—
700,000 shares
|
$0 | 31 Mar 2026 |
| Point72 Asset Management, L.P. |
13F
13D/G
Company
|
6.2%
from 13D/G
|
$918,869
194,264 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
24
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
32
Q2 2026 holders
1
Holder diff
-31
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend